TL;DR: Cigna Healthcare modified MM 0446 for metatarsophalangeal joint replacement of the hallux, effective September 26, 2025. Both CPT 28899 and HCPCS L8699 are classified as Experimental/Investigational/Unproven under this Cigna metatarsophalangeal joint replacement coverage policy — here's what your billing team needs to do before claims go out the door.

Cigna Healthcare's MM 0446 policy governs partial and total replacement of the first metatarsophalangeal (MTP) joint for hallux valgus or hallux rigidus caused by degenerative joint disease. The September 26, 2025 modification affects how you code and document these procedures, with CPT 28899 (unlisted foot procedure) and HCPCS L8699 (prosthetic implant, not otherwise specified) both landing in experimental/investigational/unproven territory. If your practice or facility performs first MTP joint replacements and bills Cigna, expect denials on these codes without a clear strategy in place.


Quick-Reference Table

Field Detail
Payer Cigna Healthcare
Policy Metatarsophalangeal Joint Replacement — Coverage Position Criteria
Policy Code MM 0446
Change Type Modified
Effective Date September 26, 2025
Impact Level High
Specialties Affected Podiatry, Orthopedic Surgery, Foot and Ankle Surgery
Key Action Flag CPT 28899 and HCPCS L8699 in your charge capture as experimental/investigational before billing Cigna for first MTP joint replacement procedures

Cigna Metatarsophalangeal Joint Replacement Coverage Criteria and Medical Necessity Requirements 2025

The Cigna metatarsophalangeal joint replacement coverage policy addresses a specific clinical scenario: partial or total replacement of the first MTP joint in patients with persistent, severe, and disabling symptoms. The underlying conditions driving these procedures are hallux valgus and hallux rigidus, both resulting from degenerative joint disease of the first MTP joint.

Here's the central problem for billing teams. Cigna's position under MM 0446 in the Cigna system is that MTP joint replacement procedures — billed via CPT 28899 or with implant device costs captured under HCPCS L8699 — do not meet medical necessity standards for routine coverage. These codes are classified as Experimental/Investigational/Unproven. That classification is not a maybe. It means Cigna will not reimburse these claims under standard coverage.

The distinction matters because hallux valgus and hallux rigidus are genuinely debilitating conditions. Patients with severe degenerative joint disease of the first MTP joint often reach the point where fusion (arthrodesis) or implant replacement feels like the only path forward. Cigna's coverage policy says the evidence for joint replacement specifically doesn't support coverage — regardless of how symptomatic the patient is. This is a clinical evidence position, not a documentation gap you can paper over.

Prior authorization won't solve this one. When a payer classifies a procedure as experimental/investigational, prior auth is typically not even an option — the coverage policy itself blocks reimbursement at the plan level. Confirm this for each specific Cigna plan type your patients carry, since plan-level exclusions can vary. If you're uncertain how this applies to your patient mix, talk to your billing consultant or compliance officer before the September 26, 2025 effective date creates a backlog of denied claims.


Cigna MTP Joint Replacement Exclusions and Non-Covered Indications

Under MM 0446, Cigna treats first metatarsophalangeal joint replacement as Experimental/Investigational/Unproven. Both the procedure itself and the associated prosthetic implant device carry this designation.

CPT 28899 is an unlisted procedure code. It's the code your team reaches for when a more specific CPT doesn't exist for the exact procedure performed. For first MTP joint replacement, 28899 is the standard billing vehicle — and under this coverage policy, it's the code Cigna specifically calls out as non-covered. The same applies to HCPCS L8699, which captures the implant cost as a prosthetic not otherwise specified.

The experimental/investigational/unproven designation is Cigna's way of saying: the clinical evidence doesn't yet support this procedure as safe and effective enough for routine coverage. It's not a prior auth hurdle. It's a coverage wall. No amount of documentation of conservative treatment failure or functional impairment changes that designation under the current policy.

This matters especially for orthopedic and podiatric practices that perform first MTP joint replacements as an alternative to fusion. Surgeons and patients may prefer joint replacement for mobility preservation. Cigna's coverage policy doesn't follow that clinical preference — at least not yet.


Coverage Indications at a Glance

Indication Status Relevant Codes Notes
Partial MTP joint replacement for hallux valgus (degenerative joint disease) Experimental/Investigational/Unproven CPT 28899, HCPCS L8699 Not covered under MM 0446; claim denial expected
Total MTP joint replacement for hallux valgus (degenerative joint disease) Experimental/Investigational/Unproven CPT 28899, HCPCS L8699 Not covered under MM 0446; claim denial expected
Partial MTP joint replacement for hallux rigidus (degenerative joint disease) Experimental/Investigational/Unproven CPT 28899, HCPCS L8699 Not covered under MM 0446; claim denial expected
+ 1 more indications

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

This policy is now in effect (since 2025-09-26). Verify your claims match the updated criteria above.

Cigna MTP Joint Replacement Billing Guidelines and Action Items 2025

The effective date is September 26, 2025. If you're reading this after that date, act now. If you're reading this before, you have a short window to get ahead of denials.

#Action Item
1

Flag CPT 28899 and HCPCS L8699 in your charge capture system today. Add a billing alert or charge capture rule that fires whenever 28899 is selected for a first MTP joint replacement. The alert should remind coders and billers that Cigna classifies this as experimental/investigational under MM 0446.

2

Audit any Cigna claims for first MTP joint replacement billed on or after September 26, 2025. If 28899 or L8699 went out the door without a denial strategy in place, identify those claims now. You need to know your exposure before remit comes back.

3

Notify surgeons performing first MTP joint replacements. Your medical director or lead surgeon needs to know Cigna's position under MM 0446. If patients have Cigna coverage and surgery is planned, the informed consent process should address the likely absence of reimbursement. This is also where a financial counselor should engage the patient directly — before the procedure, not after.

+ 3 more action items

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

Sample Version Diff Line-by-line changes
Previous VersionCurrent Version
Coverage is considered experimental and investigational for all indicationsCoverage is considered medically necessary when specific criteria are met
Prior authorization is not requiredPrior authorization is required for initial treatment
Documentation must include clinical historyDocumentation must include clinical history
+ 1 more action items

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

CPT, HCPCS, and ICD-10 Codes for Metatarsophalangeal Joint Replacement Under MM 0446

The Cigna MM 0446 policy does not list any covered CPT codes for first MTP joint replacement. All codes identified in the policy carry an experimental/investigational/unproven designation. No ICD-10-CM codes are specified in the policy data.

Not Covered / Experimental Codes

Code Type Description Status Under MM 0446
28899 CPT Unlisted procedure, foot or toes Experimental/Investigational/Unproven
L8699 HCPCS Prosthetic implant, not otherwise specified Experimental/Investigational/Unproven

A note on CPT 28899: This unlisted code requires a special report when submitted to any payer. That report should describe the procedure in detail, reference comparable procedures, and justify medical necessity. For Cigna claims under MM 0446, that special report won't overcome the experimental designation — but document it anyway. If you pursue an appeal, a well-constructed special report is part of your foundation.

A note on HCPCS L8699: This code captures the implant device cost. The fact that Cigna lists it separately under MM 0446 signals they're watching for implant billing specifically — not just the surgical procedure code. Don't assume the device cost slips through even if the procedure claim is somehow processed. Both codes carry the same designation. Both will generate claim denial.

No ICD-10 codes are specified in MM 0446 as published. The clinical context — hallux valgus, hallux rigidus, and degenerative joint disease of the first MTP joint — maps to codes in the M20 and M19 ranges, but Cigna's policy does not tie coverage criteria to specific diagnosis codes. That means diagnosis coding alone won't change the outcome. The procedure classification drives the denial.


Get the Full Picture for CPT 28899

Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.

🔍 Search by any code 🔔 Real-time alerts 📊 Line-by-line diffs ⏰ Deadline tracking
Get Full Access → $99/mo · 14-day money-back guarantee